Sports and trauma as risk factors for motor neurone disease: New Zealand case-control study - Chen GX, Douwes J, van den Berg LH, Glass B, McLean D, 't Mannetje AM.
OBJECTIVES: To assess whether sports, physical trauma and emotional trauma are associated with motor neurone disease (MND) in a New Zealand case-control study (2013-2016). METHODS: In total, 321  MND cases and 605 population controls were interview... (Source: SafetyLit)
Source: SafetyLit - April 4, 2022 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Ronnie Corbett: Star's secret motor neurone diagnosis left him needing '24-hour care'
RONNIE CORBETT sadly passed away aged 85 back in March 2016. Just after his death, Corbett's devoted wife revealed more about the entertainer's ill health and his amyotrophic lateral sclerosis diagnosis that came as a complete shock to them both. (Source: Daily Express - Health)
Source: Daily Express - Health - April 2, 2022 Category: Consumer Health News Source Type: news

Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting
First data showing OCREVUS treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive MS will be presentedEvrysdi data continue to demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophyLonger-term efficacy and safety forEnspryng inneuromyelitisoptica spectrum disorder reinforce previously seen resultsAdditional data across neurological disorders, including Alzheimer ’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatmentBasel, 25 March...
Source: Roche Investor Update - March 25, 2022 Category: Pharmaceuticals Source Type: news

Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting
First data showing OCREVUS treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive MS will be presentedEvrysdi data continue to demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophyLonger-term efficacy and safety forEnspryng inneuromyelitisoptica spectrum disorder reinforce previously seen resultsAdditional data across neurological disorders, including Alzheimer ’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatmentBasel, 25 March...
Source: Roche Media News - March 25, 2022 Category: Pharmaceuticals Source Type: news

‘Emotional moment’: locked-in patient communicates with family via implant
New technology allows patients to communicate but at slow paceA completely locked-in patient is able to type out words and short sentences to his family, including what he would like to eat, after being implanted with a device that enables him to control a keyboard with his mind.The findings, published in Nature Communications,overturn previous assumptions about the communicative abilities of people who have lost all voluntary muscle control, including movement of the eyes or mouth, as well as giving a unique insight into what it ’s like to be in a “locked in” state.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - March 22, 2022 Category: Science Authors: Linda Geddes Tags: Science Health World news Motor neurone disease Source Type: news

New Genetic Test Finds Hidden Neurological Diseases New Genetic Test Finds Hidden Neurological Diseases
Difficult-to-diagnose hereditary muscular and motor neuron diseases can now be detected using technology about the size of a stapler.WebMD Health News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 18, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

New data for Roche ’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA)
Long-term efficacy data from the pivotal SUNFISH study confirm increases in motor function are sustained at three years while adverse events decreased over the same periodPart 2 of SUNFISH showedEvrysdi demonstrated a marked improvement in, orstabilisation of, motor function after two years compared to an untreated external control groupLatest interim results from the RAINBOWFISH study demonstrate that the majority of babies treated withEvrysdi for at least 12 months were able to stand and walk within timeframes typical of healthy babiesMore than 5,000 patients have been treated withEvrysdi to date, from newborns to people...
Source: Roche Investor Update - March 16, 2022 Category: Pharmaceuticals Source Type: news

New data for Roche ’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA)
Long-term efficacy data from the pivotal SUNFISH study confirm increases in motor function are sustained at three years while adverse events decreased over the same periodPart 2 of SUNFISH showedEvrysdi demonstrated a marked improvement in, orstabilisation of, motor function after two years compared to an untreated external control groupLatest interim results from the RAINBOWFISH study demonstrate that the majority of babies treated withEvrysdi for at least 12 months were able to stand and walk within timeframes typical of healthy babiesMore than 5,000 patients have been treated withEvrysdi to date, from newborns to people...
Source: Roche Media News - March 16, 2022 Category: Pharmaceuticals Source Type: news

Roche to present new Evrysdi data at MDA 2022 and highlight expanding neuromuscular disease portfolio
Evrysdi ® (risdiplam) data further confirm long-term efficacy and safety data in a broad range of people with spinal muscular atrophy (SMA)Latest interim results from the RAINBOWFISH study demonstrate that the majority of babies treated with Evrysdi for at least 12 months were able to sit, stand and walk within timeframes typical of healthy babiesNew gene therapy data in boys living with Duchenne muscular dystrophy (DMD) reports encouraging results from early stage study supporting its progress into global pivotal Phase III EMBARK studyBasel, 08 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data...
Source: Roche Media News - March 8, 2022 Category: Pharmaceuticals Source Type: news

Roche to present new Evrysdi data at MDA 2022 and highlight expanding neuromuscular disease portfolio
Evrysdi ® (risdiplam) data further confirm long-term efficacy and safety data in a broad range of people with spinal muscular atrophy (SMA)Latest interim results from the RAINBOWFISH study demonstrate that the majority of babies treated with Evrysdi for at least 12 months were able to sit, stand and walk within timeframes typical of healthy babiesNew gene therapy data in boys living with Duchenne muscular dystrophy (DMD) reports encouraging results from early stage study supporting its progress into global pivotal Phase III EMBARK studyBasel, 08 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data...
Source: Roche Investor Update - March 8, 2022 Category: Pharmaceuticals Source Type: news

Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)
Basel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA). The sNDA submission incorporates interim data from the RAINBOWFISH study, which shows the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting, standing, walking and maintained the ability to swallow following 12 months of treatment.  “Treating very youn...
Source: Roche Media News - January 25, 2022 Category: Pharmaceuticals Source Type: news

Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)
Basel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA). The sNDA submission incorporates interim data from the RAINBOWFISH study, which shows the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting, standing, walking and maintained the ability to swallow following 12 months of treatment.  “Treating very youn...
Source: Roche Investor Update - January 25, 2022 Category: Pharmaceuticals Source Type: news

Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA)
Interim data submitted to the FDA show majority of pre-symptomatic babies treated withEvrysdi for at least one year were able to sit, stand and walk within timeframes typical of healthy babies, as well as maintain swallowingEvrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to dateBasel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age w...
Source: Roche Media News - January 25, 2022 Category: Pharmaceuticals Source Type: news

Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)
Interim data submitted to the FDA show majority of pre-symptomatic babies treated withEvrysdi for at least one year were able to sit, stand and walk within timeframes typical of healthy babies, as well as maintain swallowingEvrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to dateBasel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age w...
Source: Roche Investor Update - January 25, 2022 Category: Pharmaceuticals Source Type: news

£50m motor neurone disease funding 'offers glimmer of hope'
Campaigners including former policeman Chris Johnson hope a cure can be found in the next five years. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 15, 2021 Category: Consumer Health News Source Type: news